Rasmus Rask Kragh Jørgensen, Lasse Hjort Jakobsen, Sandra Eloranta, Karin E. Smedby, Robert Schou Pedersen, Judit M. Jørgensen, Michael Roost Clausen, Peter Brown, Anne Ortved Gang, Inger-Lise Gade, Thomas Stauffer Larsen, Mats Jerkeman, Tarec Christoffer El-Galaly
{"title":"R-CHOP与R-CHOEP治疗年轻高危弥漫大B细胞淋巴瘤患者的疗效：一项基于丹麦人群的观察性研究。","authors":"Rasmus Rask Kragh Jørgensen, Lasse Hjort Jakobsen, Sandra Eloranta, Karin E. Smedby, Robert Schou Pedersen, Judit M. Jørgensen, Michael Roost Clausen, Peter Brown, Anne Ortved Gang, Inger-Lise Gade, Thomas Stauffer Larsen, Mats Jerkeman, Tarec Christoffer El-Galaly","doi":"10.1111/ejh.14275","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Purpose</h3>\n \n <p>Etoposide to standard R-CHOP is used for high-risk diffuse large B-cell lymphoma (DLBCL) in some countries. Due to the lack of randomized trials, a real-world data study using matching methods was used to test the potential effectiveness of R-CHOEP over R-CHOP.</p>\n </section>\n \n <section>\n \n <h3> Patients and Methods</h3>\n \n <p>This study included patients from the Danish Lymphoma Register diagnosed between 2006 and 2020 at the age of 18–60 years with de novo DLBCL and age-adjusted IPI ≥2. R-CHOEP treated patients were matched 1:1 without replacement to R-CHOP treated patients using a hybrid exact and genetic matching technique. Primary endpoints were progression-free survival (PFS) and overall survival (OS).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>In total, 396 patients were included; 213 received R-CHOEP and 183 received R-CHOP. Unadjusted 5-year PFS and OS for R-CHOEP were 69% (95% Confidence intervals [CI]; 63%–76%) and 79% (CI;73%–85%) versus 62% (CI;55%–70%) and 76% (CI;69%–82%) for R-CHOP (log-rank test, PFS <i>p</i> = .25 and OS <i>p</i> = .31). A total of 127 patients treated with R-CHOEP were matched to 127 patients treated with R-CHOP. Matching-adjusted 5-year PFS and OS were 65% (CI; 57%–74%) and 79% (CI; 72%–84%) for R-CHOEP versus 63% (CI; 55%–73%) and 79% (CI;72%–87%) for R-CHOP (log-rank test, PFS <i>p</i> = .90 and OS <i>p</i> = .63).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The present study did not confirm superiority of R-CHOEP over R-CHOP for young patients with high-risk DLBCL.</p>\n </section>\n </div>","PeriodicalId":11955,"journal":{"name":"European Journal of Haematology","volume":"113 5","pages":"641-650"},"PeriodicalIF":2.3000,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ejh.14275","citationCount":"0","resultStr":"{\"title\":\"Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: A Danish observational population-based study\",\"authors\":\"Rasmus Rask Kragh Jørgensen, Lasse Hjort Jakobsen, Sandra Eloranta, Karin E. Smedby, Robert Schou Pedersen, Judit M. Jørgensen, Michael Roost Clausen, Peter Brown, Anne Ortved Gang, Inger-Lise Gade, Thomas Stauffer Larsen, Mats Jerkeman, Tarec Christoffer El-Galaly\",\"doi\":\"10.1111/ejh.14275\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Purpose</h3>\\n \\n <p>Etoposide to standard R-CHOP is used for high-risk diffuse large B-cell lymphoma (DLBCL) in some countries. Due to the lack of randomized trials, a real-world data study using matching methods was used to test the potential effectiveness of R-CHOEP over R-CHOP.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Patients and Methods</h3>\\n \\n <p>This study included patients from the Danish Lymphoma Register diagnosed between 2006 and 2020 at the age of 18–60 years with de novo DLBCL and age-adjusted IPI ≥2. R-CHOEP treated patients were matched 1:1 without replacement to R-CHOP treated patients using a hybrid exact and genetic matching technique. Primary endpoints were progression-free survival (PFS) and overall survival (OS).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>In total, 396 patients were included; 213 received R-CHOEP and 183 received R-CHOP. Unadjusted 5-year PFS and OS for R-CHOEP were 69% (95% Confidence intervals [CI]; 63%–76%) and 79% (CI;73%–85%) versus 62% (CI;55%–70%) and 76% (CI;69%–82%) for R-CHOP (log-rank test, PFS <i>p</i> = .25 and OS <i>p</i> = .31). A total of 127 patients treated with R-CHOEP were matched to 127 patients treated with R-CHOP. Matching-adjusted 5-year PFS and OS were 65% (CI; 57%–74%) and 79% (CI; 72%–84%) for R-CHOEP versus 63% (CI; 55%–73%) and 79% (CI;72%–87%) for R-CHOP (log-rank test, PFS <i>p</i> = .90 and OS <i>p</i> = .63).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>The present study did not confirm superiority of R-CHOEP over R-CHOP for young patients with high-risk DLBCL.</p>\\n </section>\\n </div>\",\"PeriodicalId\":11955,\"journal\":{\"name\":\"European Journal of Haematology\",\"volume\":\"113 5\",\"pages\":\"641-650\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-07-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ejh.14275\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Haematology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ejh.14275\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Haematology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ejh.14275","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
目的：在一些国家，高风险弥漫大B细胞淋巴瘤（DLBCL）在标准R-CHOP基础上加用依托泊苷。由于缺乏随机试验，我们采用匹配方法进行了一项真实世界数据研究，以检验R-CHOEP相对于R-CHOP的潜在疗效：这项研究纳入了丹麦淋巴瘤登记处2006年至2020年间诊断的18-60岁新发DLBCL患者，年龄调整后IPI≥2。R-CHOEP治疗患者与R-CHOP治疗患者采用混合精确配对和基因配对技术进行1:1配对，不进行替换。主要终点为无进展生存期（PFS）和总生存期（OS）：结果：共纳入 396 例患者，其中 213 例接受了 R-CHOEP 治疗，183 例接受了 R-CHOP 治疗。R-CHOEP未经调整的5年PFS和OS分别为69%（95%置信区间[CI]；63%-76%）和79%（CI；73%-85%），而R-CHOP为62%（CI；55%-70%）和76%（CI；69%-82%）（对数秩检验，PFS p = .25，OS p = .31）。共有 127 名接受 R-CHOEP 治疗的患者与 127 名接受 R-CHOP 治疗的患者进行了配对。匹配调整后，R-CHOEP的5年PFS和OS分别为65%（CI；57%-74%）和79%（CI；72%-84%），而R-CHOP分别为63%（CI；55%-73%）和79%（CI；72%-87%）（对数秩检验，PFS p = .90，OS p = .63）：本研究并未证实，对于年轻的高危DLBCL患者，R-CHOEP优于R-CHOP。
Effectiveness of R-CHOP versus R-CHOEP for treatment of young patients with high-risk diffuse large B-cell lymphoma: A Danish observational population-based study
Purpose
Etoposide to standard R-CHOP is used for high-risk diffuse large B-cell lymphoma (DLBCL) in some countries. Due to the lack of randomized trials, a real-world data study using matching methods was used to test the potential effectiveness of R-CHOEP over R-CHOP.
Patients and Methods
This study included patients from the Danish Lymphoma Register diagnosed between 2006 and 2020 at the age of 18–60 years with de novo DLBCL and age-adjusted IPI ≥2. R-CHOEP treated patients were matched 1:1 without replacement to R-CHOP treated patients using a hybrid exact and genetic matching technique. Primary endpoints were progression-free survival (PFS) and overall survival (OS).
Results
In total, 396 patients were included; 213 received R-CHOEP and 183 received R-CHOP. Unadjusted 5-year PFS and OS for R-CHOEP were 69% (95% Confidence intervals [CI]; 63%–76%) and 79% (CI;73%–85%) versus 62% (CI;55%–70%) and 76% (CI;69%–82%) for R-CHOP (log-rank test, PFS p = .25 and OS p = .31). A total of 127 patients treated with R-CHOEP were matched to 127 patients treated with R-CHOP. Matching-adjusted 5-year PFS and OS were 65% (CI; 57%–74%) and 79% (CI; 72%–84%) for R-CHOEP versus 63% (CI; 55%–73%) and 79% (CI;72%–87%) for R-CHOP (log-rank test, PFS p = .90 and OS p = .63).
Conclusion
The present study did not confirm superiority of R-CHOEP over R-CHOP for young patients with high-risk DLBCL.
期刊介绍：
European Journal of Haematology is an international journal for communication of basic and clinical research in haematology. The journal welcomes manuscripts on molecular, cellular and clinical research on diseases of the blood, vascular and lymphatic tissue, and on basic molecular and cellular research related to normal development and function of the blood, vascular and lymphatic tissue. The journal also welcomes reviews on clinical haematology and basic research, case reports, and clinical pictures.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
